**INTRODUCTION:** Low anti-Factor Xa (aFXa) levels, indicative of inadequate enoxaparin dosing, has a significant association with 90-day venous thromboembolism (VTE) events. We examined the pharmacodynamics of enoxaparin 40mg twice daily and its correlation with aFXa, post-operative VTE, and bleeding.

**METHODS:** Adult patients were admitted after plastic and reconstructive surgery procedures and received enoxaparin 40mg twice daily. Peak aFXa levels, which quantify enoxaparin's anti-thrombotic effect, were drawn. Symptomatic VTE or clinically relevant bleeding at 90 days was identified. The comparison group included 94 patients who received enoxaparin 40mg once daily from a previous clinical trial, funded by the Plastic Surgery Foundation, at our institution.

**RESULTS:** 98 patients who received enoxaparin 40mg twice daily are enrolled in this ongoing study. 9.2% of patients had low peak aFXa levels and 60.2% of patients had in-range peak aFXa levels. 30.6% of patients had high aFXa levels, including 12.2% of the population who were therapeutically anti-coagulated. Patient weight predicted enoxaparin metabolism (r^2^value of 0.45). When compared to patients given enoxaparin 40mg once daily, patients given enoxaparin 40mg twice daily 1) were significantly less likely to have low aFXa (9.2% vs. 44.1%, p\<0.001), 2) had non-significant increase in clinically relevant bleeding (6.1% vs. 3.2%%, p=0.34), and 3) had significantly fewer post-operative VTE (0% vs. 5.3% p=0.021).

**CONCLUSION:** With enoxaparin 40mg twice daily, only 9.2% of patients receive inadequate prophylaxis based on aFXa level. This is relevant because prior work has correlated inadequate prophylaxis with symptomatic VTE after plastic surgery procedures. When compared to patients who receive enoxaparin 40mg per day, patients who receive enoxaparin 40mg twice daily had significantly fewer VTE and had non-significant increase in clinically relevant bleeding. Ongoing patient recruitment will further define the effectiveness and safety profile of this intervention.
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